Blade Therapeutics Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 31

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 8

Blade Therapeutics General Information

Description

Provider of novel anti-fibrotic therapies intended to revolutionize the treatment of fibrotic disease. The company's therapies address various fibrotic diseases and their underlying pathophysiology to potentially reverse the fibrotic damage to tissue, enabling patients to get cured of the disease without any side effects.

Contact Information

Formerly Known As
FibroRX
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 50 Francisco Street
  • Suite 450
  • San Francisco, CA 94133
  • United States
+1 (650) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Blade Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Secondary Transaction - Private 00000 Completed Generating Revenue
11. PIPE 08-Nov-2021 0000 Cancelled Generating Revenue
10. Reverse Merger 08-Nov-2021 00000 00000 Cancelled Generating Revenue
9. Later Stage VC (Series C) 23-Oct-2019 0000 00000 00000 Completed Generating Revenue
8. Debt - General 08-Mar-2019 0000 000.00 Completed Clinical Trials - Phase 2
7. Early Stage VC 13-Nov-2018 000.00 Completed Clinical Trials - Phase 2
6. Accelerator/Incubator 000.00 Completed Clinical Trials - Phase 2
5. Accelerator/Incubator 30-Jun-2016 000.00 Completed Clinical Trials - Phase 2
4. Early Stage VC (Series B) 08-Jun-2016 $45M $51.5M 000.00 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series A) 06-Jul-2015 $6M $6.5M 0000 Completed Clinical Trials - Phase 2
To view Blade Therapeutics’s complete valuation and funding history, request access »

Blade Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C-1 00,000,000 00.000000 00.0 00.00 00.00 00 00.00 00
Series C 00,000,000 00.000000 00.0 00.00 00.00 00 00.00 00.000
Series B 43,000,000 $0.000100 $0.07 $1.05 $1.05 1x $1.05 39.26%
Series A 6,500,000 $0.000100 $0.09 $1 $1 1x $1 5.93%
To view Blade Therapeutics’s complete cap table history, request access »

Blade Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Provider of novel anti-fibrotic therapies intended to revolutionize the treatment of fibrotic disease. The company's the
Drug Discovery
San Francisco, CA
31 As of 2022
00000
000000 - 000 00000

000000

t ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exerci
0000 000000000
Boston, MA
000 As of 0000
00000
000000000 00000

000000

idunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud ex
0000 000000000
Boston, MA
0 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Blade Therapeutics Competitors (58)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Rhythm Pharmaceuticals Formerly VC-backed Boston, MA 000 00000 000000000 00000
Aileron Therapeutics Formerly VC-backed Boston, MA 0 00000 000000000 00000
ZyVersa Therapeutics Formerly VC-backed Weston, FL 0 000.00 00000000 000.00
Apeptico Venture Capital-Backed Vienna, Austria 00.00 0000000000 00.00
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
You’re viewing 5 of 58 competitors. Get the full list »

Blade Therapeutics Patents

Blade Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3148822-A1 Calpain inhibitors and uses thereof for treating neurological disorders Pending 31-Jul-2019 0000000000
AU-2020323923-A1 Calpain inhibitors and uses thereof for treating neurological disorders Pending 31-Jul-2019 0000000000
EP-4003336-A1 Calpain inhibitors and uses thereof for treating neurological disorders Pending 31-Jul-2019 0000000000
US-20220257570-A1 Calpain inhibitors and uses thereof for treating neurological disorders Inactive 31-Jul-2019 0000000000
EP-4003336-A4 Calpain inhibitors and uses thereof for treating neurological disorders Pending 31-Jul-2019 A61P25/28 0
To view Blade Therapeutics’s complete patent history, request access »

Blade Therapeutics Executive Team (16)

Name Title Board Seat Contact Info
Harry Dietz Co-Founder
Jeffrey Evans Senior Manager Operations and Finance
You’re viewing 2 of 16 executive team members. Get the full list »

Blade Therapeutics Board Members (11)

Name Representing Role Since
Cameron Wheeler Ph.D Deerfield Management Board Member 000 0000
Luke Evnin Ph.D MPM BioImpact Board Member 000 0000
Mark Timney Self Chairman 000 0000
Rana Al-Hallaq Ph.D Pfizer Ventures Board Member 000 0000
William Slattery Deerfield Management Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Blade Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Blade Therapeutics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
OneVentures Venture Capital Minority 000 0000 000000 0
Bristol-Myers Squibb Corporation Minority 000 0000 000000 0
Deerfield Management Venture Capital Minority 000 0000 000000 0
Novartis Institutes for BioMedical Research Corporation Minority 000 0000 000000 0
MPM BioImpact Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Blade Therapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ATXCo 25-Sep-2019 0000000000 Biotechnology
To view Blade Therapeutics’s complete acquisitions history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »